MENU
XPH
AS OF
Dec 24 closing price
Price
$57.56
Change
+$1.02 (+1.80%)
Net Assets
235.71M
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
+Compare
XPH
ETF ticker: NYSE ARCA
AS OF
Dec 24 closing price
Price
$57.56
Change
+$1.02 (+1.80%)
Net Assets
235.71M

XPH stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U... Show more

Category: #Health
XPH
Setup
Setup
Daily Signal:
Description
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
View AI-Driven Trading for XPH
Interact to see
Advertisement
A.I.Advisor
a Summary for XPH with price predictions
Dec 24, 2025

XPH in downward trend: price expected to drop as it breaks its higher Bollinger Band on December 08, 2025

XPH broke above its upper Bollinger Band on December 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In of the 33 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for XPH moved out of overbought territory on December 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for XPH turned negative on December 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XPH advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 207 cases where XPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street® SPDR® S&P® PhrmctlsETF ETF is 62.9B. The market cap for tickers in the group ranges from 444.02M to 963.92B. LLY holds the highest valuation in this group at 963.92B. The lowest valued company is EOLS at 444.02M.

High and low price notable news

The average weekly price growth across all stocks in the State Street® SPDR® S&P® PhrmctlsETF ETF was 4%. For the same ETF, the average monthly price growth was 8%, and the average quarterly price growth was 42%. OMER experienced the highest price growth at 74%, while OCUL experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the State Street® SPDR® S&P® PhrmctlsETF ETF was -48%. For the same stocks of the ETF, the average monthly volume growth was -61% and the average quarterly volume growth was -61%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 64
Price Growth Rating: 44
SMR Rating: 69
Profit Risk Rating: 69
Seasonality Score: 21 (-100 ... +100)
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
XPH
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com